MRK · 10-Q · 2026Q3 · Full report

Other Income (Expense), Net

Merck & Co., Inc. · 2026-11-04 · Importance 18 · Surprise 14

Other expense, net, was $27 million in the third quarter of 2026, compared with $238 million of income in the third quarter of 2025. For the first nine months of 2026, the company reported $262 million of expense, versus $281 million of income in the comparable 2025 period. The unfavorable year-over-year changes primarily reflected higher net interest expense, partly offset by higher net income from investments in equity securities.

Key facts

• Merck recorded a $68 million realized gain in the first nine months of 2026 related to its existing investment in TARGAN. source
• Other expense, net, was $27 million in Q3 2026 versus $238 million of income in Q3 2025; for the first nine months of 2026 it was $262 million of expense versus $281 million of income in 2025. source